Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Related Citations for PubMed (Select 24420815)

1.

Molecular therapy of colorectal cancer: progress and future directions.

Weng W, Feng J, Qin H, Ma Y.

Int J Cancer. 2015 Feb 1;136(3):493-502. doi: 10.1002/ijc.28722. Epub 2014 Feb 7. Review.

PMID:
24420815
2.
3.

Targeted therapeutic agents for colorectal cancer.

Chee CE, Sinicrope FA.

Gastroenterol Clin North Am. 2010 Sep;39(3):601-13. doi: 10.1016/j.gtc.2010.08.017. Review.

4.

Emerging therapies for colorectal cancer.

Hezel AF, Ryan DP.

Expert Opin Investig Drugs. 2007 Jun;16(6):867-76. Review.

PMID:
17501698
5.

Targeting PI3K signaling as a therapeutic approach for colorectal cancer.

Zhang J, Roberts TM, Shivdasani RA.

Gastroenterology. 2011 Jul;141(1):50-61. doi: 10.1053/j.gastro.2011.05.010. Review.

PMID:
21723986
6.

Novel targets for anticancer treatment development in colorectal cancer.

Macarulla T, Ramos FJ, Capdevila J, Saura C, Tabernero J.

Clin Colorectal Cancer. 2006 Nov;6(4):265-72. Review.

PMID:
17241511
7.

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.

Gadgeel SM, Wozniak A.

Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16. Review.

PMID:
23332287
8.

The promise of mTOR inhibitors in the treatment of colorectal cancer.

Kim DD, Eng C.

Expert Opin Investig Drugs. 2012 Dec;21(12):1775-88. doi: 10.1517/13543784.2012.721353. Epub 2012 Sep 16. Review.

PMID:
22978346
9.

Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives.

Marques I, Araújo A, de Mello RA.

World J Gastroenterol. 2013 Nov 28;19(44):7955-71. doi: 10.3748/wjg.v19.i44.7955. Review.

10.

Targeting NF-kappaB for colorectal cancer.

Sakamoto K, Maeda S.

Expert Opin Ther Targets. 2010 Jun;14(6):593-601. doi: 10.1517/14728221003769903. Review.

PMID:
20367537
11.

Epithelial ovarian cancer: focus on targeted therapy.

Pliarchopoulou K, Pectasides D.

Crit Rev Oncol Hematol. 2011 Jul;79(1):17-23. doi: 10.1016/j.critrevonc.2010.07.004. Epub 2010 Aug 2. Review.

PMID:
20674385
12.

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.

Ruzzo A, Graziano F, Canestrari E, Magnani M.

Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. Review.

PMID:
20088793
13.

Epidermal growth factor receptor: pathway, therapies, and pipeline.

Goffin JR, Zbuk K.

Clin Ther. 2013 Sep;35(9):1282-303. doi: 10.1016/j.clinthera.2013.08.007. Review.

PMID:
24054705
14.

Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.

Winder T, Lenz HJ.

Gastroenterology. 2010 Jun;138(6):2163-76. doi: 10.1053/j.gastro.2010.02.005. Review.

PMID:
20420953
15.

On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling.

McDonald SL, Silver AR.

Colorectal Dis. 2011 Apr;13(4):360-9. doi: 10.1111/j.1463-1318.2009.02149.x. Review.

PMID:
20015264
16.

A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.

Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P.

Cancer Treat Rev. 2014 Jul;40(6):701-15. doi: 10.1016/j.ctrv.2014.02.006. Epub 2014 Feb 28. Review.

PMID:
24731471
17.

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S.

Lancet Oncol. 2011 Jun;12(6):594-603. doi: 10.1016/S1470-2045(10)70209-6. Epub 2010 Dec 14. Review.

PMID:
21163703
18.

Targeting the PI3K-AKT-mTOR signaling network in cancer.

Khan KH, Yap TA, Yan L, Cunningham D.

Chin J Cancer. 2013 May;32(5):253-65. doi: 10.5732/cjc.013.10057. Review.

19.

New approaches in angiogenic targeting for colorectal cancer.

Prat A, Casado E, Cortés J.

World J Gastroenterol. 2007 Nov 28;13(44):5857-66. Review.

20.

Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

Antonarakis ES, Carducci MA, Eisenberger MA.

Cancer Lett. 2010 May 1;291(1):1-13. doi: 10.1016/j.canlet.2009.08.012. Epub 2009 Aug 29. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk